ATM and breast cancer: On the other hand, the majority of ATM variants described so far in sporadic leukemia and breast cancers are missense base substitutions (Prokopcova et al. 2007; Broeks et al. 2008), making it difficult to distinguish missense mutations that affect protein function from sequence polymorphisms with no effect on normal ATM protein activity.